Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor
Medical Research Laboratories, Highland Heights, Kentucky, U.S.A.
* Correspondence: Evan Stein, MD, PhD, Medical Research Laboratories, 2 Tesseneer Drive, Highland Heights, Kentucky 41076, U.S.A.
Abstract
Phase I/II studies in patients with hypercholesterolaemia have explored the safety and efficacy of ezetimibe mono-therapy and co-administration with a statin. In an 8-week dose-ranging study, daily doses of 1–40 mg of ezetimibe reduced low-density lipoprotein cholesterol (LDL-C) levels in a fairly flat dose-dependent manner. A second dose-ranging study confirmed that optimal efficacy, of 19% reduction in LDL-C level at 12 weeks, was achieved with the 10-mg dose. A dose-regimen, or dose-scheduling, study of morning versus evening dosing produced similar reductions of LDL-C levels, showing that timing of dosing does not affect treatment response. Pooled efficacy results from these two monotherapy studies confirmed that ezetimibe 10 mg.day–1 significantly (
) reduced LDL-C levels by approximately 18%; ezetimibe also reduced triglyceride levels by approximately 5% and increased high-density lipoprotein cholesterol levels by approximately 3·5%. An additional study of 10 mg of ezetimibe co-administered with 10 mg of simvastatian showed that ezetimibe does not affect the pharmacokinetics of the statin and provides a 17% additive reduction in LDL-C levels compared with simvastatin monotherapy. Other studies with ezetimibe indicate minimal potential for drug interactions. Ongoing phase III trials are expected to confirm that ezetimibe, alone or in combination with a statin and as an adjunct to diet, provides consistent and predictable reductions in LDL-C level of 18%, with no new or worsened statin-related side-effects.
Key Words: Cholesterol absorption inhibitor • ezetimibe • hypercholesterolaemia • phase II studies • pharmacokinetic/pharmacodynamic • statins
References
- van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235 in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther. 1997;283:157–163
[Abstract/Free Full Text] - van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235 and its glucuronide, SCH60663 Br J Pharmacol. 2000;129:1748–1754[CrossRef][Web of Science][Medline]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc. 1993;269:3015–3023
[Abstract/Free Full Text] - Bays H, Drehobl M, Rosenblatt S, et al. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects: results of a dose-response study (Abstr). Atherosclerosis. 2000;151:133
- Lipka LJ, LeBeaut AP, Veltri EP, et al. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies (Abstr). J Am Coll Cardiol. 2000;35(Suppl 2A):257A
- Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin (Abstr). Atherosclerosis. 2000;151:135
- Statkevich P, Zhu Y, Kosoglou T, et al. Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin (Abstr). Clin Pharmacol Ther. 2000;67:146
- Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511
[Free Full Text] - Kosoglou T, Meyer I, Musiol B, et al. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol (Abstr). Lyon, FranceThird International Congress on Coronary Artery Disease — from Prevention to Intervention. October 2–5, 2000. p. 71
- Kosoglou T, Meyer I, Cutler DL, et al. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin (Abstr). Lyon, FranceThird International Congress on Coronary Artery Disease — from Prevention to Intervention. October 2–5, 2000. p. 101
- Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo (Abstr). Clin Pharmacol Ther. 2000;67:152
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Pattis and C. J Wiedermann Ezetimibe-Associated Immune Thrombocytopenia Ann. Pharmacother., March 1, 2008; 42(3): 430 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gadsby Review: Diabetic dyslipidaemia -- the case for using statins The British Journal of Diabetes & Vascular Disease, November 1, 2003; 3(6): 402 - 407. [Abstract] [PDF]
|
|
|
|
|
|
V. F Mauro and C. E Tuckerman Ezetimibe for Management of Hypercholesterolemia Ann. Pharmacother., June 1, 2003; 37(6): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||